A marker commonly used to determine if a patient is having a heart attack can also be used to identify stable patients at high risk for deadly cardiac events, according to a new study led by investigators at Brigham and Women’s Hospital (BWH). Using a test that is more sensitive than what is currently used in U.S. hospitals and clinics, the research team found that nearly 40 percent of patients with type 2 diabetes and stable heart disease had abnormal blood levels of the protein troponin. Patients with elevated levels of troponin were twice as likely as their counterparts to die from heart attack, stroke or other cardiovascular causes within five years. The team also found that a key therapeutic intervention known as coronary revascularization, frequently used in patients with heart attack and an abnormal troponin, did not lower stable patients’ elevated troponin levels or their risk of deadly cardiac events. The findings are published in the August 13, 2015 issue of The New England Journal of Medicine.
“The patients in our study were not having symptoms of a heart attack, and yet a remarkably high proportion of them had an abnormal troponin, suggesting they were experiencing ongoing injury to their hearts,” said lead author Brendan Everett, MD, MPH, of BWH’s Divisions of Cardiovascular Medicine and Preventive Medicine. “This test was able to identify patients at increased risk of heart attack, heart failure, or death, even after we accounted for other patient characteristics and risk factors. In the future, if we can understand what causes the abnormal troponin, we may be able to identify new strategies to treat this group of high-risk patients. One strategy we tested in this study - opening the coronary arteries of stable patients with abnormal troponin - did not reduce the risk of future heart attack or death.”
Everett and colleagues measured troponin concentrations from more than 2,200 patients who had both type 2 diabetes and stable heart disease using a highly sensitive test (a high-sensitivity electrochemiluminescence assay) that is currently in use in Europe, and is being studied for use in the U.S. After five years, 27 percent of the patients with abnormal troponin levels went on to die of a heart attack, stroke, or cardiovascular causes, compared to 13 percent of patients with normal troponin levels.
Half of the patients involved in the trial received prompt coronary revascularization - a procedure to open the coronary arteries using either stents or coronary bypass graft surgery. However, the procedure did not appear to reduce the risk of cardiovascular-related death in these stable patients with elevated troponin, nor did it reduce troponin levels.
“We know that circulating troponin concentrations reflect ongoing injury to the heart’s muscle tissue, but the causes of this ongoing injury are not completely clear. In the right clinical situation, we would typically interpret the abnormal troponin levels as indicative of an ongoing heart attack, which we often treat by finding the blocked artery and opening it; however, our results indicate that such procedures do not reduce the risk of future heart attack or death in these patients,” said Everett. “We need alternative strategies to improve outcomes in this group of high-risk patients.”
###
Other researchers who contributed to this work include Maria Mori Brooks, Helen E.A. Vlachos, Bernard R. Chaitman, Robert L. Frye and Deepak L. Bhatt for the BARI 2D Study Group.
This work was supported by grants (U01HL061744, U01HL061746, U01HL061748, U01HL063804, and R21HL121495) from the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health and by an investigator-initiated research grant from Roche Diagnostics. Everett reports receiving grant support from Roche and Novartis and fees for serving on a clinical events committee from Genzyme. Brooks reports receiving grant support from Gilead Sciences.
Chaitman reports receiving fees for serving on clinical events committees from Merck, Eli Lilly, and Novo Nordisk, and fees for serving on data safety monitoring boards from Pfizer and Sanofi-Aventis. Bhatt reports serving on advisory boards for Cardax, Medscape Cardiology, and Regado Biosciences, receiving fees for serving on a steering committee from WebMD, receiving research funding through his institution from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi-Aventis, and The Medicines Company; participating in unfunded research collaborations with FlowCo, PLx Pharma, and Takeda; and serving as an investigator in studies funded by Biotronik and St. Jude Medical though his institution.
Brigham and Women’s Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits, nearly 46,000 inpatient stays and employs nearly 16,000 people. The Brigham’s medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $600 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation’s first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses’ and Physicians’ Health Studies and the Women’s Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH’s online newsroom.
###
Elaine St. Peter
.(JavaScript must be enabled to view this email address)
617-525-6375
Brigham and Women’s Hospital